
    
      Single-center, fasted, open-label, randomized, gender-balanced, single-dose, laboratory
      blinded, two-periods, two-sequence, crossover study in 2 groups of subjects.

      In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of
      OPC approved formulation [AF] or a single 25 mg dose of OPC formulation to be submitted for
      approval [NF].

      In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of
      OPC (AF), or a single 50 mg dose of OPC (NF
    
  